Drug Delivery Systems Market: From Oral Tablets to Targeted Biologics

A powerful drug that cannot be absorbed, stays in the bloodstream too briefly or concentrates in the wrong tissue is a much less effective therapy. Drug delivery systems — the technologies and formulations that control how, when and where a drug reaches its target — are therefore as important as the active ingredient itself. The drug delivery systems market provides the technologies, devices and formulation science that enable drugs to be administered effectively and safely across oral, injectable, inhaled, transdermal and implantable routes.

This article explains the main delivery routes and technologies, the market context, the growing complexity driven by biologics and the outlook for this essential segment of the pharmaceutical industry.

Key Takeaways

• Drug delivery systems improve therapeutic outcomes by controlling drug release, protecting drugs from degradation and targeting specific tissues.
• Oral delivery remains the largest segment; injectable delivery (including biologics) is the fastest-growing.
• Biologics — proteins, monoclonal antibodies and gene therapies — require specialised delivery systems very different from small molecules.
• Wearable injectors, auto-injectors and inhalation devices are key areas of growth and innovation.

Main Delivery Routes

• Oral (tablets, capsules, liquids): the most convenient and widely used route. Drug is absorbed through the gastrointestinal tract. Controlled-release formulations extend dosing intervals and smooth blood level fluctuations.
• Injectable: subcutaneous, intramuscular or intravenous. Bypasses GI absorption, giving faster and more predictable effects. Essential for biologics that cannot survive oral administration.
• Inhalation: metered dose inhalers (MDIs) and dry powder inhalers (DPIs) deliver drugs directly to the lungs for respiratory conditions. Nebulisers are used for severe cases. Inhaled biologics and peptides are an emerging area.
• Transdermal patches: deliver drugs slowly through the skin into the bloodstream for systemic effects. Used for pain, hormone therapy, nicotine replacement and cardiovascular drugs.
• Implantable devices: drug-eluting implants, rods and microchips that provide sustained local or systemic drug release over months to years.
• Topical: creams, gels and ointments for skin conditions, with newer technologies enabling deeper penetration.
• Ophthalmic: drops, gels and implants for eye conditions including glaucoma and retinal diseases.

Controlled-Release Technology

Conventional tablets release drug rapidly, causing peaks (potential side effects) and troughs (reduced efficacy) in blood levels. Controlled-release formulations use polymer matrices, coatings or osmotic pumps to release drug slowly over hours or days. Extended-release formulations reduce dosing frequency from three times daily to once daily, improving adherence and patient quality of life. The controlled-release segment commands premium pricing over immediate-release equivalents.

Biologics and the Delivery Challenge

The fastest-growing area of pharmaceutical development is biologics — large-molecule drugs including monoclonal antibodies, proteins, vaccines and gene therapies. Most biologics cannot be taken orally because the GI tract destroys them; they must be injected. The market for biological drug delivery includes:

• Auto-injectors: prefilled devices for self-administration of biologics, used for conditions such as rheumatoid arthritis, psoriasis and multiple sclerosis.
• Wearable injectors: patch-like devices that deliver large volumes of biologic subcutaneously over 5–60 minutes, allowing home administration of drugs previously given by intravenous infusion at clinics.
• Prefilled syringes: ready-to-inject syringes that reduce preparation errors and contamination.
• Lyophilised formulations: freeze-dried drugs reconstituted before injection, extending stability and shelf life.

Market Context

The drug delivery systems market spans formulation development, drug-device combination products and the devices themselves. See Actual Market Research's report on the global drug delivery systems market for detailed analysis and projections. The market is closely linked to pharmaceutical R&D pipelines, with novel delivery technologies used to differentiate products from competitors and extend drug life cycles. For broader healthcare sector context, see our guide to the medical imaging market.

Nanotechnology in Drug Delivery

Nanoparticle drug delivery systems — liposomes, polymeric nanoparticles, lipid nanoparticles and nanocrystals — enable targeted delivery to tumours, improved solubility of poorly water-soluble drugs and protection of sensitive molecules from degradation. Lipid nanoparticles became widely known as the delivery system for mRNA COVID-19 vaccines and are now being applied to cancer immunotherapy, rare diseases and a wide range of RNA therapeutics. This is one of the most active areas of drug delivery R&D.

Digital Health Integration

Smart inhalers with sensors track when and how patients use their inhaler, providing data to patients and clinicians. Connected insulin pens record doses. Electronic adherence monitoring devices confirm that tablets have been taken. These digital drug delivery systems improve adherence and generate real-world data on drug use in clinical practice.

Key Growth Drivers

Biologic Drug Growth

Biologics now represent the majority of new drug approvals by value. Their complex delivery requirements are driving innovation in auto-injectors, wearable devices and novel formulation technologies.

Chronic Disease Management

Conditions requiring lifelong therapy — diabetes, rheumatoid arthritis, cardiovascular disease — benefit greatly from convenient, patient-friendly delivery systems that support adherence.

Oncology Pipeline

Many of the most valuable cancer therapies are biologics or targeted small molecules requiring sophisticated delivery. Antibody-drug conjugates (ADCs) combine targeted delivery with cytotoxic drugs, representing a large and growing segment.

Challenges

• Regulatory complexity for drug-device combination products requiring both drug and device approvals.
• Cold chain requirements for biologics that must be kept refrigerated throughout distribution.
• Manufacturing complexity for nanoparticle and biologic formulations compared to simple oral tablets.
• Intellectual property strategy around delivery systems, which can be contested when generics seek to substitute branded delivery devices.

Regional Outlook

North America is the largest market, driven by high pharmaceutical spending and a large biologic pipeline. Europe is the second largest, with strong generics and biosimilars activity alongside novel delivery development. Asia-Pacific is growing rapidly, with large pharmaceutical manufacturing in India and China and growing domestic biologic pipelines in both countries.

Strategic Recommendations

• For pharmaceutical companies: invest in drug-delivery partnerships early in development — the right delivery system is often as important as the molecule.
• For device manufacturers: develop auto-injector and wearable injection platforms that can serve multiple biologic drugs across different indications.
• For investors: drug delivery technology companies with protected platforms serving the growing biologic pipeline offer attractive, recurring licensing revenue.

Frequently Asked Questions

What is a drug delivery system?

A formulation, device or technology that controls how, when, where and at what rate a drug is released in or administered to the body.

Why can't most biologics be taken orally?

Large biological molecules such as monoclonal antibodies and proteins are digested and inactivated by enzymes in the gastrointestinal tract before they can be absorbed.

What are wearable injectors?

Patch-like devices worn on the body that deliver large volumes of biologic drug subcutaneously over minutes, allowing patients to self-administer therapies at home rather than visiting a clinic for intravenous infusion.

What are lipid nanoparticles?

Tiny fat-based particles used to encapsulate and deliver sensitive molecules such as mRNA into cells. They became widely known as the delivery system for COVID-19 mRNA vaccines.

Patient Adherence and Connected Devices

Drug delivery innovation increasingly addresses patient adherence — the extent to which patients take their medications as prescribed. Non-adherence is estimated to cause approximately 50% of treatment failures in chronic diseases and costs healthcare systems billions annually in avoidable complications and hospitalisations. Delivery device design can improve adherence through convenience (once-daily vs multiple-dose), reduced pain (refined needle technology, topical anaesthetics), digital connectivity (smart inhalers that record dose time and technique) and dose reminder features. Long-acting injectable formulations (weekly, monthly or quarterly depot injections) fundamentally change the adherence dynamic by removing the need for daily self-administration.

Connected drug delivery devices — smart inhalers, connected autoinjectors, electronic pill dispensers — generate adherence data that can be shared with healthcare providers and used to tailor treatment. Smart inhaler platforms from Propeller Health (now ResMed), Adherium and Hailie record the time and GPS location of each puff, providing objective adherence data and correlating inhalation technique with symptom patterns. For patients with severe asthma or COPD who deny non-adherence, objective data changes the clinical conversation. Pharmaceutical companies are increasingly bundling connected devices with biologic therapies to support patient services programmes and generate real-world outcomes data. For wearable sensor context, see our guide to the wearable technology market.

Conclusion

The drug delivery systems market is evolving alongside the pharmaceutical industry it serves — moving from simple tablets to sophisticated biological delivery devices and nanoparticle systems. For pharmaceutical companies, investing in delivery technology is a strategic imperative. Contact Actual Market Research for detailed analysis of pharmaceutical and drug delivery markets.